global western blotting market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 6.7% during the forecast period. Advances in technology, increasing government funding for biomedical research, increasing demand for personalized medicine, and increasing HIV prevalence are key factors driving the market growth.

Get Sample PDF: https://www.marketsandmarkets.com/requestsampleNew.asp?id=235810711

Key Market Players of Western Blotting Market:

Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Techne Corporation (US), and Merck KGaA (Germany) are the prominent players operating in the western blotting market.

Covid-19 Impact on the Global Western Blotting Market

The COVID-19 outbreak has boosted research activity due to efforts to understand the dynamics of the infection. Because of the pandemic, companies have scaled up their operations for testing and tracking the infection. This provides a chance for growth in profits for companies operating in the NGS and PCR markets. The shift in demand for COVID-19, neurobiology, and oncology research has created a huge scope for testing solutions, such as western blotting, flow cytometry, ELISA, and drugs for researchers and laboratories.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235810711

Opportunity: Emerging economies

The Asia Pacific, Latin America, and the Middle East Africa are expected to offer potential growth opportunities to market players in the coming years due to the diversified healthcare markets in these regions and increasing RD initiatives to develop innovative proteomic and genomic techniques along with the development of personalized medicine. Additionally, developments in research infrastructure and the low-cost manufacturing advantage of emerging APAC countries are expected to encourage market players to invest in this region in the coming years.

The focus on proteomics research has increased in developing countries, such as China, Brazil, Australia, and India. In these countries, proteomics research is mainly focused on mapping the human proteome and determining the mechanism of action of drugs. Moreover, the establishment of the Proteomics Society, India (PSI) has provided proteomic scientists and researchers in the country with significant opportunities to form research collaborations and conduct workshops on proteomics.

Recent Developments

• In September 2021, PerkinElmer, Inc. (US) acquired BioLegend (US), a leading provider of life science antibodies and reagents, including primary antibodies and western blot secondary reagents. This acquisition enhances the company’s existing western blotting product portfolio.
• In August 2021, Abcam Plc (UK) acquired BioVision Inc. (US), a global supplier of life science research tools for research, diagnostics, and drug discovery. The company is a leading provider of biochemical and cell-based assays and produces a wide portfolio of other products, including recombinant proteins, antibodies, enzymes, and biochemical compounds for immunoassay technologies such as western blotting
• In April 2021, Bio-Techne Corporation (US) launched Abby, a next-generation chemiluminescence system that automates traditional western blotting

Speak to our analyst for a discussion on the above findings: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=235810711